BTK structure.BTK belongs to the Tec family of protein tyrosine kinases and is composed of the PH (pleckstrin homology), TH (Tec homology), SH3 (Src homology 3) SH2 (Src homology 2), and SH 1/TK (Src homology1/Tyrosine kinase) domains. Binding sites for BTK substrates, inhibitors, an...
BTK and PI3K Inhibitors in Development for Chronic Lymphocytic LeukemiaMark Weiss, MD
14. Kaptein A, de Bruin G, Hoek M E. Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies: American Society of Hematology, 2018. 15. Song Y, Xu W, Song Y, et al. Pooled Ana...
[1] Wen, T., Wang, J., Shi, Y. et al. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia 35, 312–332 (2021). [2] Sun SL, Wu SH, Kang JB et al. Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors aga...
1.Jian Hong,et al, Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially ...
Clinical research progress of BTK inhibitors in the treatment of mantle cell lymphoma Sishi XU1,Peipei. YE2 RichHTML 8 PDF (PC) 54 摘要/Abstract 摘要: 套细胞淋巴瘤(MCL)是一种少见的B细胞非霍奇金淋巴瘤,兼有惰性淋巴瘤和侵袭性淋巴瘤的临床病理特点,近十几年,针对MCL开发了许多新的治疗方法,其中...
To evaluate cellular potency of Btk inhibitors, phosphorylations of Btk and PLC- γ were analyzed by Western blotting in Ramos cells, a human Burkitt's lymphoma cell line. ABC-type DLBCL cell line, OCI-Ly10 was used to evaluate anti-tumor efficacy of Btk inhibitors. The ibrutinib-resistant ...
参考资料：1. Wen T, Wang J, Shi Y, et al. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances[J].Leukemia,?2021, 35(2): 312-332.2. 刘康,王亮.BTK抑制剂耐药机制及应对策略[J].中国癌症防治杂志,2022,14(01):104-110.3. 《BTK抑制剂全球市场分析》，丰硕...
BTK结构 资料来源:Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances BTK在细胞内多种信号通路中都有关键作用,比如BCR信号通路,Toll样受体信号通路的传导以及FcγRI等,BTK与许多血液恶性肿瘤和自身免疫系统疾病有关,因此BTK是治疗白血...
The following small-molecule Btk inhibitors in development were listed there: Stage of Company Compound Indications Development Pharmacyclics, Ibrutinib/ R/R CLL/SLL, MCL, Phase Ib/ Janssen PCL-32765 FL, DLBCL, MM, IIPhase indolent NHL, III(CLL/ MALT/MZL NHL) Pharmacyclics, PCL-32765 + R/R...